Thermo Fisher Scientific (NYSE:TMO – Get Free Report) issued its quarterly earnings results on Thursday. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32, FiscalAI reports. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company posted $4.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific updated its FY 2026 guidance to 24.930-25.330 EPS.
Here are the key takeaways from Thermo Fisher Scientific’s conference call:
- Thermo Fisher reported a strong second quarter, with revenue up 10% to $11.99 billion, adjusted EPS up 13% to $6.03, and organic revenue growth of 5% ahead of prior guidance.
- Management said customer activity strengthened across end markets, with particular momentum in pharma/biotech, plus positive growth in academic and government, industrial and applied, and diagnostics and healthcare.
- The company raised full-year 2026 guidance for both revenue and EPS, now expecting $47.4 billion-$48.1 billion of revenue and adjusted EPS of $24.93-$25.33, reflecting stronger second-half expectations.
- Several growth initiatives performed well, including Clario and filtration/separation acquisitions, which management said are integrating smoothly and contributing to higher acquisition revenue and EPS expectations for the year.
- Thermo Fisher announced it will divest its microbiology business in the third quarter, and used $1 billion of expected proceeds for share repurchases in Q2; management said the divestiture will modestly reduce 2026 revenue and EPS.
Thermo Fisher Scientific Trading Up 8.9%
Shares of Thermo Fisher Scientific stock opened at $573.43 on Friday. Thermo Fisher Scientific has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market capitalization of $213.10 billion, a price-to-earnings ratio of 31.52, a PEG ratio of 2.33 and a beta of 0.87. The stock has a 50 day moving average of $491.42 and a 200 day moving average of $513.08.
Thermo Fisher Scientific Announces Dividend
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Morgan Stanley reissued an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Finally, Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $606.45.
Read Our Latest Research Report on TMO
Insider Activity at Thermo Fisher Scientific
In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Thermo Fisher Scientific
A number of institutional investors have recently made changes to their positions in TMO. Sunbelt Securities Inc. boosted its position in shares of Thermo Fisher Scientific by 5.3% during the fourth quarter. Sunbelt Securities Inc. now owns 573 shares of the medical research company’s stock worth $332,000 after buying an additional 29 shares during the period. Evansbrook LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $215,000. Birchwood Financial Partners Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Strive Financial Group LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $2,209,000. Finally, Blue Sparrow LLC DE purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $16,167,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.
More Thermo Fisher Scientific News
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, topping estimates, while revenue rose 10.5% year over year to $11.99 billion and also beat forecasts. Reuters article
- Positive Sentiment: The company said organic revenue grew 5%, with stronger activity in pharma and biotech helping offset broader industry caution. Motley Fool transcript
- Positive Sentiment: Thermo Fisher raised full-year FY 2026 guidance to $24.93-$25.33 in EPS and $47.4 billion-$48.1 billion in revenue, signaling management expects demand trends to continue improving. MSN article
- Positive Sentiment: Several reports noted price target upgrades and strong post-earnings sentiment, which added to the stock’s momentum. Yahoo Finance article
- Neutral Sentiment: Analyst and media commentary also framed the results as part of a broader medtech rebound, but this is more backdrop than a direct catalyst. Yahoo Finance article
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
